MedPath

Neomycin

Generic Name
Neomycin
Brand Names
Casporyn HC, Cortisporin, Cortisporin-TC, Dioptrol, Diosporin, Diphen, Maxitrol, Neo-polycin, Neo-polycin HC, Neo-synalar, Neosporin Ointment, Neosporin Plus Maximum Strength, Neosporin Plus Maximum Strength Cream, Neosporin Solution, Procomycin, Statrol, Triple Antibiotic, Viaderm Kc
Drug Type
Small Molecule
CAS Number
1404-04-2
Unique Ingredient Identifier
I16QD7X297

Overview

Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. Neomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.

Indication

Oral neomycin sulfate is indicated as an adjunctive therapy in hepatic coma (portal-system encephalopathy) by reducing ammonia-forming bacteria in the intestinal tract. It is strongly recommended that oral neomycin is only used in infections that are proven or strongly suspected to be caused by susceptible bacteria to reduce the risk of the development of drug-resistant bacteria. Neomycin, in combination with polymyxin B sulfates and hydrocortisone in otic suspensions, is used in the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the antibiotics. This otic formulation is also used in the treatment of infections of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics. The ophthalmic solution containing neomycin in combination with polymyxin B sulfates and dexamethasone is used to treat steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists.

Associated Conditions

  • Allergic Contact Dermatitis
  • Allergic Skin Reaction
  • Atopic Dermatitis
  • Atopic Dermatitis (AD) of the external ear canal
  • Bacterial diarrhoea
  • Burns
  • Carbuncle
  • Contact Dermatitis
  • Cradle Cap
  • Dermatitis
  • Diarrhea
  • Discoid Lupus Erythematosus (DLE)
  • Ear infection bacterial
  • Ear infection bacterial caused by susceptible bacteria
  • Gastrointestinal Tract Infections
  • Hepatic coma
  • Hidradenitis Suppurativa (HS)
  • Hot Water Burns (Scalds)
  • Impetigo
  • Impetigo contagious
  • Infantile Eczema
  • Infected skin ulcer
  • Infection of the outer ear caused by susceptible bacteria
  • Infectious diarrhea
  • Inflammatory Reaction caused by Acne
  • Intertrigo
  • Itching caused by Infection
  • Lichen Planus (LP)
  • Localized Infection caused by susceptible bacteria
  • Nail infection
  • Neurodermatitis
  • Otitis Externa
  • Postoperative Wound Infection
  • Psoriasis Vulgaris (Plaque Psoriasis)
  • Pustular Dermatosis
  • Pustular acne
  • Radiodermatitis
  • Secondarily Infected Eczema
  • Secondary Bacterial Infection
  • Skin Burn
  • Skin Infections
  • Skin Irritation
  • Skin Ulcer
  • Solar erythema
  • Wound Infections
  • Abrasions
  • Bacterial skin infections
  • Blistering caused by Staphylococcus
  • Erythematous eruptions
  • Intertriginous erythema of the anogenital
  • Ocular bacterial infections caused by susceptible bacteria
  • Resistant to other corticosteroids Dermatosis
  • Susceptible Bacterial Infections

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2024/12/24
Early Phase 1
Not yet recruiting
2023/12/18
Not Applicable
Completed
2023/11/28
Phase 4
Recruiting
2023/08/23
Phase 2
Not yet recruiting
2023/03/22
N/A
Recruiting
Uzsoki Hospital
2022/10/25
Phase 4
Recruiting
2021/01/28
Phase 2
Active, not recruiting
2018/09/10
Phase 4
Recruiting
2018/07/20
Not Applicable
UNKNOWN
2018/06/14
Phase 4
Completed

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
MWI
13985-608
OPHTHALMIC
3.5 mg in 1 g
3/23/2015
Aidarex Pharmaceuticals LLC
33261-551
OPHTHALMIC
3.5 mg in 1 mL
8/14/2018
Bausch & Lomb Incorporated
24208-780
OPHTHALMIC
3.5 mg in 1 g
6/30/2023
DIRECT RX
61919-113
OPHTHALMIC
3.5 mg in 1 g
1/21/2020
NuCare Pharmaceuticals,Inc.
68071-4229
AURICULAR (OTIC)
3.5 mg in 1 mL
6/16/2023
Physicians Total Care, Inc.
54868-1070
OPHTHALMIC
3.5 mg in 1 mL
6/1/2012
Trifecta Pharmaceuticals USA
69396-061
TOPICAL
3.5 mg in 100 g
5/12/2025
Padagis US LLC
0574-4144
OPHTHALMIC
3.5 mg in 1 g
11/9/2018
Medimetriks Pharmaceuticals
43538-940
TOPICAL
3.5 mg in 1 g
1/10/2023
Phoenix Pharmaceutical, Inc.
57319-343
OPHTHALMIC
3.5 mg in 1 g
9/30/2010

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
NEO-BETASONE CREAM
SIN04129P
CREAM
0.5% w/w
3/28/1990
NEO-CORTISONE CREAM
SIN04113P
CREAM
500 mg/100 g
3/28/1990
PROCTOSEDYL SUPPOSITORY
SIN01717P
SUPPOSITORY
10 mg
6/8/1988
UNIFLEX-N CREAM
SIN01930P
CREAM
0.5% w/w
6/23/1988
MAXITROL STERILE OPHTHALMIC SUSPENSION
SIN04358P
SOLUTION
3500 iu/ml
5/2/1990
BANEOCIN POWDER
SIN00678P
POWDER
5000 iu/g
5/3/1988
POLYBAMYCIN OINT.
SIN04413P
OINTMENT
3.5 mg/g
5/3/1990
POLYDEXA EAR DROPS
SIN04945P
SOLUTION
650000 iu/100 ml
7/16/1990
POLYGYNAX VAGINAL CAPSULE
SIN07745P
CAPSULE
35000 iu
6/15/1994
DEXTRACIN EYE/EAR DROPS
SIN00959P
SOLUTION
0.5% w/v
5/10/1988

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
Neomycin Sulfate Tablets
国药准字H14021961
化学药品
片剂
4/20/2020
Neomycin Sulfate Tablets
国药准字H31020916
化学药品
片剂
7/4/2024
Neomycin Sulfate Tablets
国药准字H31020799
化学药品
片剂
5/12/2020
Neomycin Sulfate Tablets
国药准字H61021913
化学药品
片剂
12/11/2020
Neomycin Sulfate Tablets
国药准字H11020691
化学药品
片剂
11/20/2020
Neomycin Sulfate Tablets
国药准字H44021092
化学药品
片剂
1/13/2020
Neomycin Sulfate Tablets
国药准字H41021162
化学药品
片剂
7/15/2020
Neomycin Sulfate Tablets
国药准字H32020292
化学药品
片剂
7/7/2020
unguentum neomycini sulftis
国药准字H44024845
化学药品
软膏剂
1/6/2021
unguentum neomycini sulftis
国药准字H31022262
化学药品
软膏剂
1/15/2020

Help Us Improve

Your feedback helps us provide better drug information and insights.

© Copyright 2025. All Rights Reserved by MedPath